98%
921
2 minutes
20
Purpose: To observe choroidal and retinal changes in patients with acute leukemia in the remission stage using ultra-widefield swept-source optical coherence tomography angiography (SS-OCTA).
Methods: This cross-sectional study included 10 patients with acute leukemia in the remission stage (10 eyes) and 12 age-matched healthy controls (12 eyes). Demographic data, disease duration, and laboratory parameters were recorded. SS-OCTA was used to scan the 12 × 12 mm macular area. The retina and choroid were divided into five concentric circles with diameters of 0-1 mm, 1-3 mm, 3-6 mm, 6-9 mm, and 9-12 mm. OCTA parameters, including the thicknesses of retina and choroid, the vessel densities of superficial vascular complexes (SVC) and deep vascular complexes (DVC), the three-dimensional choroidal vascularity volume (3D-CVV), the three-dimensional choroidal vascularity index (3D-CVI), and the flow area of choriocapillaries (CC), were compared.
Results: The choroidal thickness of leukemia patients was thinner than that of the control in the 6-9 mm (P = 0.046) and 9-12 mm (P = 0.036) ranges. The 3D-CVV of patients with leukemia was significantly smaller than that in the control in the 1-3 mm (P = 0.024), 3-6 mm (P = 0.036), 6-9 mm (P = 0.038), and 9-12 mm (P = 0.028) ranges. There were no statistical differences in terms of retinal thickness, SVC, DVC, the 3D-CVI, and the flow area of CC between the groups across all ranges (all P > 0.05).
Conclusion: Thinning of the choroid and a reduction in choroidal vessel volume could be observed in acute leukemia patients in remission using ultra-widefield SS-OCTA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pdpdt.2025.104588 | DOI Listing |
Pediatr Blood Cancer
September 2025
Acute Myeloid Leukemia Sub-Committee, Association of Childhood Leukemia Study (JACLS), Japan.
Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.
Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.
Pediatr Blood Cancer
September 2025
Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA.
Moyamoya syndrome (MMS) is a chronic vasculopathy characterized by progressive stenosis of intracerebral arteries, leading to an increased risk of stroke. Children with Down syndrome (DS) are at an increased risk of co-occurring medical conditions, including MMS and leukemia. We report four patients with the triad of DS, MMS, and acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFPediatr Blood Cancer
September 2025
Centre for Reviews and Dissemination, University of York, York, UK.
Acute leukaemias are the commonest cancers in children and young people (CYP). Off-treatment surveillance is assumed to improve relapse detection, but whether this affects subsequent survival and quality of life is unclear. This systematic review searched 13 databases and two trial registries in December 2022.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
August 2025
Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI. Electronic address:
Blinatumomab is a bispecific T-cell engager that has recently transformed front-line treatment for many patients with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). It was originally studied in relapsed/refractory disease, then moved to targeting measurable residual disease (MRD), and has since been shown to improve outcomes for almost every age group when added to consolidation chemotherapy. The evidence supporting blinatumomab is most robust in adult and standard-risk pediatric age groups, but its benefit in adolescents and young adults and high-risk pediatric patients is not yet understood.
View Article and Find Full Text PDFMol Ther
September 2025
Xi'an No. 1 Hospital, First Affiliated Hospital of Northwest University, School of Medicine, Xi'an, China; Key Laboratory of Resource Biology and Biotechnology of Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an,
N6-methyladenosine (mA) modification, primarily regulated by methyltransferase-like protein 3 (METTL3), plays a pivotal role in RNA metabolism and leukemogenesis. However, the post-translational mechanisms governing METTL3 stability and function remain incompletely understood. Given the widespread occurrence of O-GlcNAcylation on nuclear and cytosolic proteins, we hypothesized that METTL3 might undergo O-GlcNAcylation, thereby influencing its stability and oncogenic function in myeloid malignancies.
View Article and Find Full Text PDF